Korsana Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
About Korsana Biosciences
Pharmaceutical Preparations, SIC 2834
Cyclerion is a biopharmaceutical company that develops treatments for serious neuropsychiatric disorders. Its lead development candidate, CYC-126, is an individualized therapy for adult patients with treatment-resistant depression. The treatment combines two intravenous anesthetics, propofol and dexmedetomidine, with a patient monitoring and delivery tool that assists anesthesiologists during administration in hospital procedure rooms or post-anesthesia care units. The company also holds legacy soluble guanylate cyclase stimulator assets, including out-licensed programs for rare kidney conditions.
The organization operates with internal executives and external consultants rather than an extensive workforce. Its clinical activities span Australia and the United States, and its patent portfolio extends across the United States, Europe, Japan, and China. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of Korsana Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Korsana Biosciences, Inc.
- Founded
- 2018
- Headquarters
- Waltham, MA
- Address
- 203 Crescent Street, Bldgs. #3/3a/4, Suite 503 02453
- Phone
- (781) 516-2325
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Massachusetts
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- KRSA
- Exchange
- Nasdaq
- IPO date
- Mar 18, 2019
- Shares outstanding
- 5M, Aug 4, 2026
- Public float
- $5.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, Sep 9, 2026; 1-for-20 reverse, Jul 28, 2023; 1-for-20 reverse, May 16, 2023
- SEC CIK
- 1755237
- CUSIP
- 23255M303
- ISIN
- US23255M3034
- EIN
- 83-1895370
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan Violin | See Remarks, Director | 207,400 |
| Regina Margaret Graul | See Remarks, Director | 156,152 |
| Matthew James Leoni | Chief Medical Officer | – |
| Mark J. Vignola | Chief Financial Officer | – |
| Rhonda M. Chicko | Chief Financial Officer | 25,018 |
| Michelle Patricia Pernice | Director | – |
| Nimish P. Shah | Director | 4,549,585 |
| Andrew Gottesdiener | Director | – |
| Healthcare Co-Invest VI L.P. Fairmount | Director | – |
| Healthcare Fund II L.P. Fairmount | Director | 9,103,729 |
| Tomas Kiselak | Director | – |
| Funds Management LLC Fairmount | Director | – |
| Peter Evan Harwin | Director | – |
| Heidi Henson | Director | – |
| Peter M. Hecht | Director | 910,312 |
| Michael J. Higgins | Director | 30,740 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Peter MHecht Ph D | $0 | $0 | $249.90K | $25 | – |
| FY2024 Regina MGraul Ph D | $874.82K | $857.82K | $249.90K | $25 | – |
| FY2023 Peter MHecht Ph D | $82.95K | -$62.47K | $559.28K | $26 | – |
| FY2023 Regina MGraul Ph D | $147.36K | $181.93K | $559.28K | $26 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had one employee and several consultants, including our Chief Financial Officer.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 11, 2026 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 27, 2026 | Name change | Name changed from Cyclerion Therapeutics, Inc. to Korsana Biosciences, Inc. |
| Apr 20, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 20, 2023 | Merger vote | Definitive merger proxy statement |
| Nov 29, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 3, 2022 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 2, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 28, 2019 | Spin-off | Registration as a new public company (Form 10), e.g. spin-off |